UNdeRstAnding Novel Variants in AcutE MyocardiaL Infarction in Young Adults

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-60
SponsorNational Heart Centre Singapore

About this trial

Cardiovascular disease (CVD) imposes significant mortality and morbidity worldwide. However, large gaps in our knowledge of CVD still exist. The clinical conundrum of the extremes of spectrums of CVD continues to baffle clinicians and researchers alike. These include patients without any major cardiovascular (CV) risk factors developing acute myocardial infarction (AMI) at a relatively young age (\<50-60 years old), while at the other end of the spectrum, there are also patients with multiple CV risk factors but with minor or no coronary artery disease. These suggest the presence of other factors that predispose these patients to AMI.Recent advancements in technology, especially in the field of genomics, metabolomics, and proteomics, have led to exciting developments in our understanding of the development and prevention of CVD and AMI. In this study, the investigators aim to identify novel gene variants associated with the onset of MI in relatively young patients with minimal standard CV risk factors such as diabetes, obesity, hypertension and hypercholesterolaemia.Through genomic, metabolomics and proteomics analyses, this may better improve our understanding of the development of CVD and AMI, potentially developing novel preventive measures to reduce the risk or delay the onset as well as tailoring management plans to improve treatment outcomes and reduce adverse events for the patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult >21 years old.

Age ≤50 years old irrespective of the presence of CV risk factors* at the time of myocardial infarction OR Age 51-60 years old with no more than 2 CV risk factor* at the time of myocardial infarction, excluding diabetes mellitus

Able to provide informed consent.

Patients who are willing and able to comply with the study visit and procedures.

Disqualifiers

Known familial hypercholesterolaemia, known vasculitides, end-stage renal disease and congenital heart disease.

Prior PAD and Stroke

Female patients who are pregnant

Patients who are non-Asian

Trial population

Relatively young patients with minimal cardiovascular risk factors who develop AMI from the respective public hospitals in Singapore

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

  • Blood Draw

    Procedure/Surgery

    3X 6mL K2-EDTA tubes, 1X 3mL K2-EDTA tubes and 1X 3.5mL SST tube - 24.5ml of blood will be collected from patient

Treatment groups

1,200 Participants
are divided into 2 treatment groups
Group A: Group 11 intervention
Group B: Group 21 intervention

Trial outcomes

Primary outcomes

1

To identify novel gene variants associated with the onset of MI in relatively young patients

Any new genetic variants through genomic analyses

Time frame
5 years

Secondary outcomes

1

To identify other novel biomarkers such as proteins, lipids and metabolites, associated with MI in young adults

Any new biomarkers during metabolomics and proteomics analyses

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.